Altimmune to present pemvidutide Phase 2b and preclinical data at AASLD 2026
Altimmune Inc. will unveil 48‑week results from its IMPACT Phase 2b study of pemvidutide in metabolic dysfunction‑associated steatohepatitis (MASH) at the AASLD meeting in Denver, November 5‑9, 2026. The trial showed reductions in liver stiffness, ELF score, liver fat and ALT versus placebo, with mild gastrointestinal side effects and fewer discontinuations. The company also disclosed preclinical data showing lower alcohol intake in a hamster model, announced the start of its PERFORMA Phase 3 MASH trial in July 2026, and reported completion of enrollment for the RESTORE Phase 2 alcohol‑associated liver disease trial in August 2026.
Why it matters
The positive Phase 2b outcomes and FDA Fast Track and Breakthrough Therapy designations suggest a clearer regulatory path and could lift Altimmune’s valuation, according to the company’s press release.
Key facts
- 1Altimmune will present data at the American Association for the Study of Liver Diseases meeting in Denver, Colorado, November 5‑9, 2026. investing.com
- 2The 48‑week IMPACT Phase 2b trial enrolled 212 participants with biopsy‑confirmed MASH and fibrosis stages F2 or F3. investing.com
- 3Participants received weekly subcutaneous pemvidutide at 1.2 mg, 1.8 mg or placebo. investing.com
- 4Pemvidutide treatment reduced liver stiffness, ELF score, liver fat and alanine aminotransferase compared with placebo. investing.com
- 5Gastrointestinal adverse events were mild to moderate, and treatment discontinuations were lower than with placebo. investing.com
- 6Preclinical data showed a reduction in mean alcohol intake in a hamster model. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.